H
0.323
0.00 (1.45%)
| Previous Close | 0.318 |
| Open | 0.320 |
| Volume | 2,298,096 |
| Avg. Volume (3M) | 3,543,584 |
| Market Cap | 61,284,324 |
| Price / Sales | 0.380 |
| Price / Book | 10.20 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2026 |
| Profit Margin | -5.24% |
| Operating Margin (TTM) | 8.11% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | 12.20% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -21.88 M |
| Levered Free Cash Flow (TTM) | -26.09 M |
| Return on Assets (TTM) | -0.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Heron Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.70% |
| % Held by Institutions | 82.47% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tejara Capital Ltd | 30 Jun 2026 | 6,510,795 |
| Jw Asset Management, Llc | 30 Jun 2026 | 3,751,073 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |